We report the cases of two severe aplastic anemia (SAA) patients who were successfully treated with syngeneic peripheral blood stem cell transplantation (PBSCT) using immunosuppression without high-dose chemotherapy or irradiation for conditioning. A 21-year-old woman with SAA of 6 years duration had been transfused heavily before transplantation and had developed refractory thrombocytopenia, chronic hepatitis and secondary hematochromatosis. Syngeneic PBSCT with immunosuppression using ATG, methylprednisolone, and cyclosporin-A was eventually performed without high-dose chemotherapy in September 1997. The second syngeneic PBSCT with the same immunosuppression was successfully performed in a 35-year-old male patient who had had SAA for 3 months in November 1998. Haemopoietic engraftment was rapid and sustained. There was no infection or mucositis during the syngeneic PBSCT. The patients are currently 9 to 22 months post-PBSCT without rejection. Our experience suggests that syngeneic PBSCT with brief immunosuppression is an effective alternative to pretransplant high-dose chemotherapy conditioning for SAA patients having syngeneic transplantation. Bone Marrow Transplantation (2000) 25, 337-339.
the first successful experience of syngeneic PBSCT with brief immunosuppression for SAA.
Case reports

Case 1
A 21-year-old Chinese woman presented with fatigue and menorrhagia in December 1989. The diagnosis of acquired SAA was made after bone marrow (BM) biopsy and a series of studies including HCV, HBV, CMV, EBV, ANA and a sugar water test at a community hospital. She received steroid pulse therapy and cyclosporin A (CsA), but in vain. She began receiving regular monthly blood transfusions at that time. For some unknown reason, a splenectomy was performed at the same community hospital in June 1996. She received blood transfusions every 2 months after that. In August 1997, her disease worsened with more frequent blood transfusions and she developed refractory thrombocytopenia. She was therefore referred to our hospital for a BMT from her identical twin sister. In September 1997, she was admitted for transplantation. Her past personal and family histories were unremarkable. Laboratory values on admission included: WBC 1.5 × 10 9 /l, PMN 0.2 × 10 9 /l, Hb 7.1 g/dl, reticulocytes 0.3%, platelets (plts) 5 × 10 9 /l, HBsAg + and HBsAb − , AST 18 U/l, ALT 32 U/l, LDH 346 U/l, serum ferritin level 6401 ng/ml, FBS 234 mg%, and HbA1C 9.3%. Her BM aspirate was hypocellular with no blasts or dysplastic cells. A trephine biopsy showed hemopoietic cellularity of less than 10%. SAA complicated with refractory thrombocytopenia, chronic HBV hepatitis, and secondary hematochromatosis was diagnosed. G-CSF (filgrastim) 10 g/kg/day was used to mobilize the donor's PBSCs. Three pheresis specimens were obtained on days 5 to 7 using double lumen CVP access with a Cobe Spectra cell separator (Cobe, Lakewood, CO, USA) after 6 days of mobilization. The PBSCs with a total 12.6 × 10 6 CD34 + cells/kg and 11 × 10 8 CD3 + cells/kg were reinfused on day 0 and day 1, after immunosuppression, as follows: methylprednisolone 20 mg/kg/day for 3 days (on days −4, −3 and −2), then 1 mg/kg/day for 1 week, and tapered over 2 weeks; antithymocyte globulin (ATG) 10 mg/kg/day for 5 days (from day −4 to 0); and CsA 3 mg/kg/day in two divided doses for 2 weeks (from day −1 to 12), then tapered over 2 weeks. After PBSC reinfusion, G-CSF 300 g/day was given until the WBC Ͼ4 × 10 9 /l for 2 consecutive days. The patient received ofloxacin 200 mg orally twice daily from day −4 until resolution of the neutropenia or the onset of fever, and fluconazole 200 mg orally daily for 2 weeks for bacterial and fungal prevention. The blood CsA level was monitored twice a week to keep the trough level between 200 and 350 ng/dl.
The whole transplant course was eventually without any complication except a slight increase in the serum bilirubin level to 3.3 g/dl, which returned to normal after the CsA dose was reduced. Hemopoietic engraftment was rapid and sustained. Her ANC was over 1.0 × 10 9 /l on day 5, and by day 10, her platelet count had reached 104 × 10 9 /l without any platelet transfusion after PBSC reinfusion. After complete BM recovery, she received a regular phlebotomy of 300 cc every 2 to 3 weeks. The patient has remained well with a normal blood count. Her serum ferritin level has decreased to 2677 ng/ml.
Case 2
A 35-year-old man presented with dizziness and bleeding gums in September 1997. His past personal and family histories were unremarkable. Initial laboratory data showed: WBC 2.0 × 10 9 /l, PMN 0.4 × 10 9 /l, Hb 4.6 g/dl, reticulocytes 0.7%, platelets 6 × 10 9 /l. Acquired idiopathic SAA was diagnosed after BM biopsy and a series of studies including HCV, HBV, CMV, EBV, ANA, and a sugar water test on admission. He had platelet and packed RBC transfusions for his bleeding and anemia. Then he received conventional androgen and prednisolone 1 mg/kg/day therapy for 2 months, but without improvement. An identical twin brother was documented by HLA-typing and short tandem repeat (STR). The patient was then offered syngeneic PBSCT.
In November 1998, the patient received a transplant of syngeneic PBSC with the same immunosuppression that was used in case 1. G-CSF (filgrastim) 10 g/kg/day was used to mobilize the donor's PBSCs. Two pheresis specimens were obtained on days 5 and 6, using double lumen CVP access with a Cobe Spectra cell separator after 5 days of mobilization. One unit of single donor pheresis platelets and 4 units of packed RBCs were given to the patient before PBSCT. The PBSCs with a total 8.4 × 10 6 CD34 + cell/kg and 7.2 × 10 8 CD3 + cell/kg were reinfused on day 0 and day 1 with the same immunosuppression regimen of methylprednisolone, ATG, and CsA. After PBSCT, he also received G-CSF 300 g/day and the same regimen of ofloxacin and fluconazole to prevent bacterial and fungal infections. The whole transplant course was successful and without any complication. BM engraftment was rapid and sustained. By day +5, the ANC had increased to Ͼ1.0 × 10 9 /l and the platelet count had increased to Ͼ50 × 10 9 /l from day +8 without any platelet transfusion after PBSC reinfusion. By the day +12, he had complete normalization of blood count with WBC 6.1 × 10 9 /l, PMN 3.6 × 10 9 /l, Hb 11.6 g/dl and platelets 202 × 10 9 /l. The patient remained well with a normal blood count after 9 months of follow-up.
Discussion
Immunosuppressive therapy with ATG and CsA has been proved to produce very good results in previously untreated patients. However, a majority of patients have only partial BM recovery and a high incidence of relapse, or evolution to myelodysplastic syndrome or paroxysmal noctural hemoglobulinuria within 2 years. 4 BMT from an HLA-identical sibling or twin is the treatment of choice for young patients with severe aplastic anemia. As recently reported in the largest series of International Bone Marrow Transplant Registry (IBMTR) patients, the risk of graft rejection is up to 70% in syngeneic BMT for SAA without the use of a prior conditioning regimen. However, the side-effects of high-dose chemotherapy conditioning are considerable. A high infection rate and more bleeding may be induced by pretransplant high-dose chemotherapy. The risk of early mortality was increased to 29% (5/17) by conditioning BMT in the IBMTR report. In addition, patients whose BMT was not preceded by conditioning had better longterm survival. 5 Considerable data suggest that the majority of causes of aplastic anemia are either immune-mediated or involve a defect of hematopoietic stem cells. [6] [7] [8] Therefore, hematopoietic stem cells combined with immunosuppression may be an effective alternative to high-dose chemotherapy conditioning for syngeneic BMT. PBSCT has the advantage of accelerating haemopoietic engraftment after transplantation. In addition, it also contains large numbers of stem cells and T cells, which may have the advantage of enhancing engraftment. The necessity for high-dose chemotherapy for pretransplant conditioning is questionable in syngeneic transplantation, particularly in patients with a high risk of mortality, such as those with refractory thrombocytopenia, or hematochromatosis. These cases confirm the potential for rapid and sustained engraftment characteristically associated with G-CSF-mobilized PBSC grafts and brief immunosuppression.
